El interés en corto de Novavax da a los inversores una idea del grado en que los inversores apuestan por la caída de las acciones de Novavax. Los datos de interés en corto se actualizan cada dos semanas.

Novavax (NASDAQ:NVAX) Bolsa, Informe de interés en corto

Novavax

Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. Novavax works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The Company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from Europe.

News

NVAX

Las acciones de Novavax caen a medida que las preocupaciones sobre la disminución de la demanda de vacunas afectan al sector.

Acciones de Novavax (NVAX) caen un 9,8% tras anuncio de Moderna

Las acciones de Novavax Inc (NVAX) suben un 13,5% tras un informe de los CDC sobre el aumento de enfermedades respiratorias en EE.UU.

Acciones de Novavax (NVAX) suben tras informe de los CDC sobre enfermedades respiratorias

Novavax Inc

The CDC issued a health advisory Thursday recommending that hospitalized patients who have tested positive for influenza be tested for the bird flu <a href="https://www.benzinga.com/general/biotech/25/01/42854890/us-records-first-human-bird-flu-death-high-levels-of-respiratory-illnesses-vaccine-stocks-rally">virus within 24 hours.&nbsp;</a>
What To Know: There have been 67 confirmed human cases of bird flu in the U.S. since 2024 and the CDC<a href="https://www.cdc.gov/bird-flu/situation-summary/index.html"> says it is</a> "watching the situation carefully and working with states to monitor people with animal exposures."
The CDC's latest H5N1<a href="https://www.cdc.gov/han/2025/han00520.html"> bird flu advisory</a> comes as new cases continue to be revealed. On Wednesday, the CDC confirmed a bird flu infection in a child in the San Francisco area who was not hospitalized and has since recovered. The CDC said it is still investigating how the child was exposed to the virus. 
Read Next: <a href="https://www.benzinga.com/general/health-care/25/01/43041254/unitedhealth-ceo-highlights-hospitals-doctors-pharmas-role-in-soaring-health-care-costs">UnitedHealth CEO Highlights Hospitals, Doctors, Pharma&#8217;s Role In Soaring Health Care Costs</a>&nbsp;
According to a Washington Post<a href="https://www.washingtonpost.com/health/2025/01/16/bird-flu-testing-patients-in-hospital/"> report</a>, Nirav Shah, CDC's principal deputy director, said the latest recommendation is meant to accelerate testing rather than increase the number of tests being performed.&nbsp;
Shah said it was prompted by cases in which infected patients were later confirmed to have bird flu, including after being discharged.
Earlier this month, the Louisiana Department of Health reported the first human death in the U.S. related to the H5N1 bird flu virus.
Vaccine Makers: Shares of vaccine-related stocks are on watch as previous bird flu developments have caused shares to spike.&nbsp;
Moderna, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) received a $176 million government contract in July to advance development of its bird flu vaccine, leveraging the same mRNA technology used in the company's COVID-19 vaccine.  
Novavax, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>) has a bird flu vaccine in clinical trials<a href="https://www.benzinga.com/general/biotech/24/11/41878334/fda-gives-green-signal-to-novavaxs-covid-19-influenza-combo-vaccine-late-stage-trial"> in addition</a> to a COVID-19-influenza combination vaccine in late-stage clinical trials. 
CureVac N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CVAC#NASDAQ">CVAC</a>) stock is also on watch as the company has started a phase I/II study on its bird flu vaccine developed in collaboration with GSK plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSK#NYSE">GSK</a>).  
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/25/01/43007213/experts-see-the-fed-on-hold-for-now-if-there-are-any-cuts-at-all-in-2025-after-decembers-sticky-consumer-inflation-report">Interest Rate Cuts &#8216;On Hold&#8230; If There Are Any At All In 2025&#8217; After December&#8217;s Sticky Consumer Inflation Report: Economists&nbsp;</a></li>
</ul>
Photo: Shutterstock

Biotech

Government

Health Care

General

CVAC

MRNA

Bird Flu Raising Red Flags Among Health Officials, CDC Urges Faster Testing

<a href="https://www.washingtonpost.com/health/2025/01/16/bird-flu-testing-patients-in-hospital/">https://www.washingtonpost.com/health/2025/01/16/bird-flu-testing-patients-in-hospital/</a>
&nbsp;
The Centers for Disease Control and Prevention says hospitals treating people for the flu should test them for avian influenza within 24 hours.

AEMD

'As Bird Flu Affects More People And Animals, CDC Urges Faster Testing' - Washington Post

Novavax's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NYSE">NVAX</a>) short percent of float has fallen 5.74% since its last report. The company recently reported that it has 36.92 million shares sold short, which is 28.74% of all regular shares that are available for trading. Based on its trading volume, it would take traders 11.49 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Novavax Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1736784016_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Novavax has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Novavax's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Novavax's peer group average for short interest as a percentage of float is 12.58%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Trading Ideas

Looking Into Novavax's Recent Short Interest

Novavax Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>) shares are trading lower by 9.8% to $8.40 during Monday&#8217;s session amid weakness in vaccine stocks after Moderna issued 2025 revenue guidance <a href="https://www.benzinga.com/25/01/42946454/moderna-expects-lower-annual-sales-expands-cost-cutting-initiatives">below analyst estimates</a>.
What To Know: Shares of several vaccine makers, including Novavax, dropped sharply on Monday as Moderna&#8217;s announcement of lower-than-expected 2025 revenue projections rattled investor confidence across the sector.
Moderna, whose stock fell around 23% Monday morning, expects 2025 revenues of $1.5 billion to $2.5 billion, significantly below the consensus of $2.95 billion, largely tied to weakening demand for its Spikevax COVID-19 vaccine and mRESVIA RSV vaccine.
Read Also: <a href="https://www.benzinga.com/news/25/01/42901509/why-novavax-nvax-stock-is-volatile-this-week">Why Novavax Stock Is Volatile This Week</a>
The news also intensified concerns about diminishing COVID-19 vaccine revenues and broader industry challenges as pandemic-driven demand continues to wane. 
What Else: Novavax, which relies heavily on its COVID-19 vaccine sales, saw its stock decline likely amid fears that heightened competition from Moderna's streamlined portfolio strategy could erode market share further.
The selloff could also reflect a broader skepticism about vaccine makers&#8217; ability to adapt to post-pandemic market realities, with investors reevaluating growth prospects and long-term demand for new and existing products in the space.
Read Also: <a href="https://www.benzinga.com/economics/macro-economic-events/25/01/42944934/wall-street-slashes-interest-rate-cut-bets-after-jobs-data-are-hikes-back-on-the-table">Wall Street Slashes Interest Rate Cut Bets After Jobs Data: Are Hikes Back On The Table?</a>
<h2 class="wp-block-heading">Should I Sell My NVAX Stock?</h2>
Whether to sell or hold a stock largely depends on an investor's strategy and risk tolerance. Swing traders may sell an outperforming stock to lock in a capital gain, while long-term investors might ride out the turbulence in anticipation of further share price growth.
Similarly, traders willing to minimize losses may sell a stock that falls a certain percentage, while long-term investors may see this as an opportunity to buy more shares at a discounted price.
Shares of Novavax have gained 94.47% year to date. This compares to the average annual return of -56.39%, meaning the stock has outperformed its historical averages. Investors can compare a stock's movement to its historical performance to gauge whether this is a normal movement or a potential trading opportunity. 
Investors may also consider market dynamics. The Relative Strength Index can be used to indicate whether a stock is overbought or oversold. Novavax stock currently has an RSI of 58.05, indicating neutral conditions.
For analysis tools, charting data and access to exclusive stock news, check out <a href="https://pro.benzinga.com/">Benzinga PRO. Try it for free.</a>

Why Novavax (NVAX) Stock Is Falling

WIIM

BNTX

Shares of vaccine stocks are trading lower after Moderna issued 2025 revenue guidance below analyst estimates.

Novavax Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>) shares dipped 11.2% to $9.60 during Wednesday&#8217;s session, pulling back<a href="https://www.benzinga.com/topic/novavax"> following recent strength. </a>
Shares of vaccine makers are volatile this week after the first bird flu death was reported in the U.S. Additionally, a recent CDC <a href="https://www.cdc.gov/respiratory-viruses/data/index.html#cdc_data_surveillance_section_2-weekly-national-summary">report</a> noted an increase in acute respiratory illness activity.
What To Know: As a company specializing in vaccine development, Novavax is positioned as a potential player in addressing such outbreaks, particularly given its history of <a href="https://www.benzinga.com/general/biotech/24/09/40688052/fda-approves-novavaxs-updated-covid-vaccine-targeting-currently-circulating-variants">creating vaccines</a> for infectious diseases.
Read Also: <a href="https://www.benzinga.com/trading-ideas/long-ideas/25/01/42897161/apples-24-year-70000-climb-since-itunes-faces-2025-test">Apple&#8217;s 24-Year 70,000% Climb Since iTunes Launch Faces 2025 Test</a>
While <a href="https://www.benzinga.com/general/biotech/25/01/42882233/bird-flu-sparks-vaccine-stock-surge-etfs-to-watch-as-h5n1-outbreak-intensifies">traditional bird flu vaccines</a> from Sanofi, CSL Seqirus and GlaxoSmithKline are already stockpiled, they target older H5N1 strains, leaving potential room for innovation and updates.
Novavax, with its proprietary recombinant nanoparticle vaccine technology, could be seen as a contender to develop a next-generation bird flu vaccine if demand grows. The bird flu outbreak, which has <a href="https://www.benzinga.com/economics/macro-economic-events/24/12/42471357/egg-hyperinflation-could-spike-grocery-prices-why-cal-maine-vital-farms-are-soaring">devastated poultry farms</a> and raised concerns about viral mutations, could also underscore the need for advanced vaccine platforms.
Investor speculation about potential government funding or contracts to combat the outbreak could likely contribute to volatility in Novavax shares, despite the CDC stating that <a href="https://www.benzinga.com/general/biotech/25/01/42882233/bird-flu-sparks-vaccine-stock-surge-etfs-to-watch-as-h5n1-outbreak-intensifies">public risk remains low</a>.
Read Also: <a href="https://www.benzinga.com/general/biotech/25/01/42882233/bird-flu-sparks-vaccine-stock-surge-etfs-to-watch-as-h5n1-outbreak-intensifies">Bird Flu Sparks Vaccine Stock Surge: ETFs To Watch As H5N1 Outbreak Intensifies</a>
<h2 class="wp-block-heading">How To Buy NVAX Stock</h2>
By now you're likely curious about how to participate in the market for Novavax &#8211; be it to purchase shares, or even attempt to bet against the company.
Buying shares is typically done through a brokerage account. You can find a list of <a href="https://www.benzinga.com/money/best-stock-trading-platforms">possible trading platforms here.</a> Many will allow you to buy ‘fractional shares,' which allows you to own portions of stock without buying an entire share. For example, some stock, like Berkshire Hathaway, or Amazon.com, can cost thousands of dollars to own just one share. However, if you only want to invest a fraction of that, brokerages will allow you to do so. 
In the the case of Novavax, which is trading at $9.60 as of publishing time, $100 would buy you 10.41 shares of stock.
If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to ‘go short' a share of stock by lending you the shares to sell. The process of shorting a <a href="https://www.benzinga.com/money/how-to-short-a-stock">stock can be found at this resource.</a> Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading &#8211; either way it allows you to profit off of the share price decline.
According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, NVAX has a 52-week high of $23.86 and a 52-week low of $3.53.
Image courtesy of <a href="https://pixabay.com/illustrations/ai-generated-stock-exchange-bull-8477673/">Pixabay</a>

Why Novavax Stock Is Volatile This Week

The U.S. reported its <a href="https://www.benzinga.com/general/biotech/25/01/42854890/us-records-first-human-bird-flu-death-high-levels-of-respiratory-illnesses-vaccine-stocks-rally">first human death</a> from the H5 bird flu strain this week, causing a spike in vaccine developer stocks Moderna (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>), Novavax (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>), CureVac (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CVAC#NASDAQ">CVAC</a>) and Pfizer (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>).
Vaccine production efforts are ramping up as health officials monitor the outbreak closely. In<a href="https://www.cdc.gov/bird-flu/situation-summary/index.html" target="_blank" rel="noreferrer noopener"> an update </a>on Monday, CDC said there have been 66 confirmed cases in the U.S. in the 2024 outbreak. 
CDC said the public risk remains low. Bird flu has severely impacted poultry farms and cattle herds across 16 states, marking the worst outbreak of its kind.
See Also: <a href="https://www.benzinga.com/news/25/01/42851023/why-novavax-nvax-stock-is-rising">Why Novavax (NVAX) Stock Is Rising</a>
<h3 class="wp-block-heading">Vaccine Providers in the Limelight</h3>
In the U.S., vaccines against H5N1 are already stockpiled. Approved shots include those from Sanofi (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>), CSL Seqirus, and ID Biomedical Corporation of Quebec, a subsidiary of GlaxoSmithKline (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSK#NYSE">GSK</a>), which collectively secured $72 million in funding from the U.S. health department in October to boost the production of bird flu vaccines. These traditional vaccines, developed years ago, target older H5N1 strains but are expected to offer some protection.
Moderna, backed by $176 million from the U.S. government's BARDA, is working on an updated mRNA H5N1 vaccine. Other players, including Pfizer and GSK (in collaboration with CureVac), are testing similar candidates.
<h3 class="wp-block-heading">ETFs in Focus</h3>
For investors who want to play the trend but are wary of choosing individual biotech stocks, here are three ETFs that offer diversified exposure to the biotech companies leading the vaccine efforts. With a mix of traditional and mRNA vaccine developers in focus, these funds could benefit as the world prepares for a potential bird flu pandemic.
iShares Genomics Immunology and Healthcare ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IDNA#NYSE">IDNA</a>) tracks the NYSE FactSet Global Genomics and Immuno Biopharma Index, and has already gained 2.5% so far this year. The fund has an expense ratio of 0.47%, and $129.97 million in assets under management (AUM). The fund has currently invested 4.48% of its assets in Moderna. Sanofi, GSK and Novavax are also part of its portfolio of 51 equity holdings.
First Trust Nasdaq Pharmaceuticals ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTXH#NASDAQ">FTXH</a>) derives its investment strategy from the Nasdaq US Benchmark Index, and has an expense ratio of 0.60%. Pfizer is one of its top holdings, with 7.28% of assets allocated to it.
SPDR S&amp;P Biotech ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XBI#NYSE">XBI</a>) mirrors the S&amp;P&nbsp;Biotechnology Select Industry&nbsp;Index, and charges a 0.35% expense ratio. Out of its present AUM of $6.37 billion, Moderna holds 2.58%. Almost 100% of its holdings are exposed to the biotechnology sector, with only about 0.04% invested in the pharmaceutical sector.
<h3 class="wp-block-heading">The Bird Flu Menace </h3>
The bird flu scare in humans ratcheted higher in late 2024 when a 13-year-old girl in Canada fell critically ill with H5N1 and required a ventilator. Around the same time, the U.S. reported its first severe case in an elderly patient in Louisiana.
Health experts warn that vigilance is key to preventing mutations that could trigger a pandemic. While the technology to develop vaccines quickly is available, governments may need to fund large-scale clinical trials in advance to ensure rapid distribution in case of a health emergency.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/01/42878295/quantum-stocks-tumble-why-rigetti-ionq-and-d-wave-are-falling">Quantum Stocks Tumble: Why Rigetti, IonQ and D-Wave Are Falling</a></li>
</ul>
Photo: Shutterstock.

Sector ETFs

ETFs

FTXH

IDNA

Bird Flu Sparks Vaccine Stock Surge: ETFs To Watch As H5N1 Outbreak Intensifies

The Louisiana Department of Health on Monday reported the first human death in the U.S. related to the H5N1 bird flu virus. The CDC is also reporting high levels of acute <a href="https://www.benzinga.com/news/25/01/42851023/why-novavax-nvax-stock-is-rising">respiratory illnesses nationwide</a>.&nbsp;
The Details: The Louisiana Department of Health said <a href="https://ldh.la.gov/news/H5N1-death">the patient</a>, who was over the age of 65 and had underlying health conditions, had been hospitalized since December after contracting the virus following &nbsp;exposure to a backyard flock and wild birds.&nbsp;
The CDC released<a href="https://www.cdc.gov/bird-flu/situation-summary/index.html"> an update </a>on the bird flu situation on Monday that said there have been 66 confirmed cases in the U.S. in the 2024 outbreak. The agency is monitoring for H5 bird flu activity in people and said the public health risk remains low at this time.&nbsp;
Read Next: <a href="https://www.benzinga.com/25/01/42821300/biden-set-to-ban-future-offshore-oil-drilling-4-stocks-to-watch">Biden Set To Ban Future Offshore Oil Drilling: 4 Stocks, 2 ETFs To Watch</a>
Additionally, other acute respiratory illnesses including COVID-19, influenza and RSV are at high levels and are increasing nationwide, according to the CDC's respiratory illness <a href="https://www.cdc.gov/respiratory-viruses/data/index.html">data channel</a>.&nbsp;
Vaccine Makers: Shares of vaccine-related stocks are trading higher following the latest bird flu developments, as well as the rise in acute respiratory illnesses.&nbsp;
Moderna, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) manufactures an FDA-approved COVID-19 vaccine and its pipeline includes<a href="https://www.benzinga.com/25/01/42825231/why-moderna-mrna-stock-is-trading-higher"> combination vaccines</a> targeting COVID-19, RSV and flu. Moderna received a $176 million government contract in July to advance development of its bird flu vaccine, leveraging the same mRNA technology used in the company&#8217;s COVID-19 vaccine.  
Shares of Novavax, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>) are also climbing. Novavax has a bird flu vaccine in clinical trials<a href="https://www.benzinga.com/general/biotech/24/11/41878334/fda-gives-green-signal-to-novavaxs-covid-19-influenza-combo-vaccine-late-stage-trial"> in addition</a> to a COVID-19-influenza combination vaccine in late-stage clinical trials. 
CureVac N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CVAC#NASDAQ">CVAC</a>) shares rose 22% on Monday and are climbing again Tuesday. The company has started a phase I/II study on its bird flu vaccine developed in collaboration with GSK plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSK#NYSE">GSK</a>). CureVac also has an agreement with GSK to develop second-generation influenza and COVID-19 vaccines. 
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/entertainment/25/01/42834240/kevin-oleary-joins-the-peoples-bid-for-tiktok-as-pending-ban-looms">Kevin O&#8217;Leary Joins The People&#8217;s Bid For TikTok As Pending Ban Looms</a>&nbsp;</li>
</ul>
Photo: Shutterstock.

Movers

US Records First Human Bird Flu Death, High Levels Of Respiratory Illnesses: Vaccine Stocks Rally

Shares of vaccine makers are trading higher after the first bird flu death was reporting in the US. Additionally, a recent CDC report noted an increase in acute respiratory illness activity.

Shares of Novavax Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>) are trading higher by 13.5% to $11.09 during Tuesday&#8217;s session following a <a href="https://www.cdc.gov/respiratory-viruses/data/index.html#cdc_data_surveillance_section_2-weekly-national-summary">CDC report</a> highlighting a sharp increase in respiratory illnesses across the U.S. The surge, attributed to higher cases of seasonal influenza, COVID-19, and RSV, has reignited interest in vaccine developers.
Additionally, the Louisiana Department of Health this week <a href="https://www.ldh.la.gov/news/H5N1-death">reported</a> the death of the first U.S. human case of H5N1, a patient over 65 with underlying conditions who contracted the virus from backyard and wild birds, with no further cases or person-to-person transmission identified. 
Heightened awareness of H5N1 risks may boost demand for avian flu vaccines and related research initiatives.
What Else: Novavax stands out for its non-mRNA approach to combating infectious diseases. The company's flagship product, Nuvaxovid, a COVID-19 vaccine, provides an alternative for individuals who cannot or prefer not to receive mRNA-based vaccines. 
Additionally, Novavax is advancing its efforts to develop combination vaccines targeting COVID-19 and influenza, which could streamline immunization efforts against multiple respiratory viruses.
The current public health landscape could underscore the relevance of Novavax&#8217;s portfolio. During the COVID-19 pandemic, the company proved its ability to scale production as a significant player in combating respiratory illnesses.
Read Also: <a href="https://www.benzinga.com/news/25/01/42821277/why-curevac-cvac-stock-is-rising">Why CureVac Stock Is Rising</a>
<h2 class="wp-block-heading">How To Buy NVAX Stock</h2>
By now you're likely curious about how to participate in the market for Novavax &#8211; be it to purchase shares, or even attempt to bet against the company.
Buying shares is typically done through a brokerage account. You can find a list of <a href="https://www.benzinga.com/money/best-stock-trading-platforms">possible trading platforms here.</a> Many will allow you to buy ‘fractional shares,' which allows you to own portions of stock without buying an entire share. For example, some stock, like Berkshire Hathaway, can cost thousands of dollars to own just one share. However, if you only want to invest a fraction of that, brokerages will allow you to do so.
In the case of Novavax, which is trading at $10.55 as of publishing time, $100 would buy you 9.48 shares of stock.
If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to ‘go short' a share of stock by lending you the shares to sell. The process of shorting a <a href="https://www.benzinga.com/money/how-to-short-a-stock">stock can be found at this resource.</a> Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading &#8211; either way it allows you to profit off of the share price decline.
According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, NVAX has a 52-week high of $23.86 and a 52-week low of $3.53.

Why Novavax (NVAX) Stock Is Rising

Shares of vaccine makers are trading higher after the first bird flu death was reporting in the US. Additionally, a recent DCD report noted an increase in acute respiratory illness activity.

<a href="https://ldh.la.gov/news/H5N1-death#:~:text=The%20Louisiana%20Department%20of%20Health,to%20have%20underlying%20medical%20conditions.">https://ldh.la.gov/news/H5N1-death#:~:text=The%20Louisiana%20Department%20of%20Health,to%20have%20underlying%20medical%20conditions.</a>
&nbsp;
<h3>Current general public health risk remains low</h3>
January 06, 2025
The Louisiana Department of Health reports the patient who had been hospitalized with the first human case of highly pathogenic avian influenza (HPAI), or H5N1, in Louisiana and the U.S. has died. The patient was over the age of 65 and was reported to have underlying medical conditions. The patient contracted H5N1 after exposure to a combination of a non-commercial backyard flock and wild birds.&nbsp;
LDH&#39;s extensive public health investigation has identified no additional H5N1 cases nor evidence of person-to-person transmission. This patient remains the only human case of H5N1 in Louisiana.&nbsp;
The Department expresses its deepest condolences to the patient&#39;s family and friends as they mourn the loss of their loved one. Due to patient confidentiality and respect for the family, this will be the final update about the patient.&nbsp;
While the current public health risk for the general public remains low, people who work with birds, poultry or cows, or have recreational exposure to them, are at higher risk.&nbsp;
The best way to protect yourself and your family from H5N1 is to avoid sources of exposure. That means avoiding direct contact with wild birds and other animals infected with or suspected to be infected with bird flu viruses.&nbsp;
Protecting yourself and others from H5N1 infection
<ul>
<li>Do not touch sick or dead animals or their droppings and do not bring sick wild animals into your home.</li>
<li>Keep your pets away from sick or dead animals and their feces.</li>
<li>Do not eat uncooked or undercooked food. Cook poultry, eggs and other animal products to the proper temperature and prevent cross-contamination between raw and cooked food.</li>
<li>Avoid uncooked food products such as unpasteurized raw milk or cheeses from animals that have a suspected or confirmed infection.</li>
<li>If you work on poultry or dairy farms, talk to your provider about getting your seasonal flu vaccination. It will not prevent infection with avian influenza viruses, but it can reduce the risk of coinfection with avian and flu viruses.</li>
<li>Report dead or sick birds or animals to the USDA toll-free at 1-866-536-7593 or the Louisiana Department of Agriculture and Forestry Diagnostic Lab at 318-927-3441.</li>
</ul>
If you have been exposed to sick or dead birds or other animals or work on a farm where avian influenza has been detected, watch for respiratory symptoms or conjunctivitis. If you develop symptoms within 10 days after exposure to sick or dead animals, tell your healthcare provider that you have been in contact with sick animals and are concerned about avian influenza. This will help them give you appropriate advice on testing and treatment. Stay home and away from others while you have symptoms.

NNVC

'LDH Reports First U.S. H5N1-Related Human Death' - Louisiana Department Of Health

Novavax's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NYSE">NVAX</a>) short percent of float has fallen 4.18% since its last report. The company recently reported that it has 39.78 million shares sold short, which is 30.97% of all regular shares that are available for trading. Based on its trading volume, it would take traders 9.77 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Novavax Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734723911_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Novavax has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Novavax's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Novavax's peer group average for short interest as a percentage of float is 14.45%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Peering Into Novavax's Recent Short Interest

<a href="https://www.gov.ca.gov/2024/12/18/governor-newsom-takes-proactive-action-to-strengthen-robust-state-response-to-bird-flu/#:~:text=What%20you%20need%20to%20know,ongoing%20cross%2Dagency%20response%20efforts" title="https://www.gov.ca.gov/2024/12/18/governor-newsom-takes-proactive-action-to-strengthen-robust-state-response-to-bird-flu/#:~:text=What%20you%20need%20to%20know,ongoing%20cross%2Dagency%20response%20efforts">https://www.gov.ca.gov/2024/12/18/governor-newsom-takes-proactive-action-to-strengthen-robust-state-response-to-bird-flu/#:~:text=What%20you%20need%20to%20know,ongoing%20cross%2Dagency%20response%20efforts</a>

CA Governor Newsom Proclaimed State Of Emergency To Further Enhance State's Preparedness And Accelerate The Bird Flu Cross-Agency Response Efforts

<a href="https://www.cdc.gov/bird-flu/situation-summary/index.html" title="https://www.cdc.gov/bird-flu/situation-summary/index.html">https://www.cdc.gov/bird-flu/situation-summary/index.html</a>

Macro Economic Events

Economics

CDC Confirms First Severe Case Of H5N1 Bird Flu In U.S. On December 13; Patient Hospitalized With Severe Case Of Avian Influenza A Virus Infection In Louisiana

<ul>
<li>Novavax continues to progress Sanofi agreement by achieving first milestone, with additional milestones and ongoing tiered royalties to come, solidifying a strong model for future partnerships</li>
<li>Novavax's COVID-19 vaccine included in Sanofi's two combination vaccine candidates for prevention of influenza and COVID-19, for which Phase 1/2 trials were initiated and Fast Track designation recently granted in the U.S.</li>
</ul>
GAITHERSBURG, Md., Dec. 13, 2024 /PRNewswire/ -- Novavax, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>), a global company advancing protein-based vaccines with its Matrix-M&#x2122; adjuvant,&nbsp;today announced progress in Q4 2024 advancing its corporate growth strategy through its partnership with Sanofi. The Company has achieved a milestone associated with its Phase 2/3 clinical trial for&nbsp;its COVID-19 vaccine in children, triggering the first $50 million milestone payment from Sanofi.

Novavax Advances Corporate Growth Strategy Through Sanofi Partnership, Including Achievement Of First $50M Milestone

HC Wainwright &amp; Co. analyst Vernon Bernardino reiterates Novavax (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>) with a Buy and maintains $19 price target.

Price Target

Reiteration

Analyst Ratings

HC Wainwright & Co. Reiterates Buy on Novavax, Maintains $19 Price Target

On CNBC's &#8220;<a href="https://www.benzinga.com/topic/mad-money-lightning-round">Mad Money Lightning Round</a>,&#8221; Jim Cramer said he is ‘not a fan' of Novavax, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>).
On Dec. 4, Novavax agreed to sell its Bohumil, Czech Republic-based manufacturing facility to Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) <a href="https://www.benzinga.com/24/12/42323263/wegovy-maker-novo-nordisk-to-buy-novavaxs-czech-republic-manufacturing-facility-for-200-million">for $200 million.</a>
Also, the Food and Drug Administration recently granted Emergency Use Authorization of the company&#8217;s<a href="https://www.benzinga.com/general/biotech/24/09/40688052/fda-approves-novavaxs-updated-covid-vaccine-targeting-currently-circulating-variants" target="_blank" rel="noreferrer noopener"> updated COVID-19 vaccine</a>. The Novavax vaccine is included in the U.S. Centers for Disease Control and Prevention (CDC) <a href="https://www.benzinga.com/general/biotech/24/09/40752686/benzingas-stock-whisper-index-5-stocks-investors-secretly-monitor-but-dont-talk-about-yet">recommendations</a>.
The vaccine is the only protein-based option available in the U.S. for people aged 12 and older for the prevention of COVID-19.
When asked about Alliance Entertainment (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LNT#NYSE">LNT</a>), Cramer said Live Nation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LYV#NYSE">LYV</a>) is a better buy.
On Oct. 31, Alliant Energy posted better-than-expected quarterly results.
Cramer said he can't get behind Nebius Group N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBIS#NASDAQ">NBIS</a>). &#8220;If I want AI, I will go for Nvidia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) as it comes down,&#8221; he added.
On Dec. 2, Nebius Group announced it entered a $700 million private placement financing agreement with institutional investors.
Innodata Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INOD#NASDAQ">INOD</a>) is now a &#8220;very expensive&#8221; stock, Cramer said. &#8220;And I just think if you take a little off the table, you can always get back in.&#8221;
On Nov. 7, Innodata reported better-than-expected third-quarter financial results.
When asked about Smith &amp; Wesson Brands (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SWBI#NASDAQ">SWBI</a>), he said, &#8220;Not my cup of tea, but I don't think it's a bad level to get involved.&#8221;
On Dec. 6, Lake Street and Craig-Hallum both downgraded the stock from Buy to Hold and cut their respective price targets from $18 to $13.
United Parcel Service, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UPS#NYSE">UPS</a>) has &#8220;gone down so much, it's been such a disappointment,&#8221; the Mad Money host said. &#8220;I still think this stock is too expensive going in to the holiday season.&#8221;
The Securities and Exchange Commission (SEC) announced on Nov. 22 that it settled charges against United Parcel Service for materially misrepresenting its earnings because it failed to follow generally accepted accounting principles (GAAP) when valuing one of its worst <a href="https://www.benzinga.com/news/legal/24/11/42151959/financial-crime-weekly-ups-pays-45m-fine-bit-mining-pays-4m-fine-for-bribery">performing businesses</a>.&nbsp;
&#8220;I don't want to recommend a stock in the AI category that's losing so much money that's up so much,&#8221; Cramer said when asked about BigBear.ai Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBAI#NYSE">BBAI</a>).
On Nov. 5, BigBear.ai reported worse-than-expected third-quarter revenue results.
Price Action:
<ul>
<li>Alliance Entertainment shares fell 0.3% to settle at $60.91 on Monday.</li>
<li>Nebius Group shares dipped 13.1% to close at $31.96.</li>
<li>Novavax shares gained 1.5% to settle at $9.07 on Monday.</li>
<li>Innodata shares fell 2.1% to $43.63 on Monday.</li>
<li>Smith &amp; Wesson Brands shares gained 4.2% to close at $11.32 on Monday.</li>
<li>UPS shares gained 2.3% to settle at $128.53 during the session.</li>
<li>BigBear.ai shares gained 8.3% to close at $3.66 on Monday.</li>
</ul>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/12/42389952/top-3-materials-stocks-that-may-rocket-higher-in-december">Top 3 Materials Stocks That May Rocket Higher In December</a></li>
</ul>
Image: Shutterstock

Markets

Media

BBAI

INOD

NBIS

NVDA

SWBI

Jim Cramer Is 'Not A Fan' Of Novavax, Says This Tech Stock Is 'Expensive'

<ul>
<li>Company continuing to work with the U.S. FDA on potential for accelerated approval pathway</li>
<li>Novavax intends to partner on both candidates to advance to filing and commercialization</li>
</ul>
GAITHERSBURG, Md., Dec. 10, 2024 /PRNewswire/ -- Novavax, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>), a global company advancing protein-based vaccines with its Matrix-M&#x2122; adjuvant,&nbsp;today announced that the first participants have been dosed in its COVID-19-Influenza Combination (CIC) and stand-alone seasonal influenza Phase 3 trial. The trial will evaluate the immunogenicity and safety of the CIC and stand-alone seasonal influenza vaccine candidates&nbsp;compared to Novavax's updated 2024-2025 COVID-19 vaccine (NVX-CoV2705)&nbsp;and a licensed seasonal influenza vaccine comparator in adults aged 65 and older.

Novavax Initiates Phase 3 Trial For COVID-19-Influenza Combination And Stand-Alone Influenza

<h2 class="wp-block-heading">New On The Block</h2>
Dental supply maker Patterson Companies Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDCO#NASDAQ">PDCO</a>) announced Thursday that it is exploring strategic options, including a sale or merger, to boost shareholder value. The company disclosed the deal process as part of its <a href="https://www.benzinga.com/24/12/42342667/dental-supplies-patterson-companies-evaluates-strategic-alternatives-after-mixed-q2-earnings-amid-challenging-end-market-environment">second-quarter financial report</a>.
<h2 class="wp-block-heading">Updates From The Block</h2>
EasyHotel is close to being sold. A billionaire-backed firm called London &amp; Regional Properties is bidding against a fund managed by Tristan Capital Partners. The auction process is in its final stages, according to <a href="https://www.bloomberg.com/news/articles/2024-11-27/billionaire-brothers-private-equity-chase-deal-for-easyhotel">Bloomberg</a>.
Ubisoft Entertainment SA (OTC:<a class="ticker" href="https://www.benzinga.com/stock/UBSFF#OTC">UBSFF</a>) is in talks with Tencent Holdings ADR (OTC:<a class="ticker" href="https://www.benzinga.com/stock/TCEHY#OTC">TCEHY</a>) <a href="https://www.benzinga.com/general/gaming/24/12/42372040/ubisoft-stock-jumps-14-after-reports-of-tencent-buyout">over a potential buyout</a>. According to Reuters, the deal would allow Ubisoft&#8217;s founders, the Guillemot family, to retain control if the company goes private. This development follows a <a href="https://www.benzinga.com/general/gaming/24/09/40801168/ubisoft-is-mismanaged-shareholders-are-hostages-investor-demands-video-game-company-go-private-aft">difficult year for Ubisoft</a>, marked by staff layoffs, disappointing sales, and the closure of several studios. Ubisoft&#8217;s stock jumped 14% after news of the buyout discussions emerged, as per <a href="https://pro.benzinga.com/dashboard">Benzinga Pro.</a>
Lightspeed Commerce Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LSPD#NYSE">LSPD</a>) is reorganizing. A majority of the restructuring charges will be incurred in the third quarter of fiscal 2025. The focus remains on &#8220;reducing the complexity of our business,&#8221; said Lightspeed founder and CEO Dax Dasilva <a href="https://investors.lightspeedhq.com/English/newsroom/news-details/2024/Lightspeed-Commerce-Announces-Strategic-Reorganization-Continues-to-Optimize-for-Profitable-Growth/default.aspx">said</a>. An analyst told <a href="https://www.paymentsdive.com/news/lightspeed-strategic-reorganization-employee-impact/734300/">Payments Dive</a> that the intent is to set Lightspeed up for a sale. JPMorgan and RBC are advising the process, according to <a href="https://www.bloomberg.com/news/articles/2024-11-07/lightspeed-looks-for-efficiencies-as-strategic-review-continues">Bloomberg</a>.
See Also: <a href="https://www.benzinga.com/general/space/24/12/42376708/nasa-mission-to-land-humans-on-moon-delayed-artemis-3-now-slated-for-mid-2027">NASA Mission To Land Humans On Moon Delayed &#8211; Artemis 3 Now Slated For&#8230;</a>
<h2 class="wp-block-heading">Off The Block</h2>
Novavax, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>) agreed to sell its Bohumil, Czech Republic manufacturing facility to Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) <a href="https://www.benzinga.com/pressreleases/24/12/n42308359/novavax-announces-sale-of-czech-republic-manufacturing-site-to-novo-nordisk-for-200-million" target="_blank" rel="noreferrer noopener">for $200 million</a>. The deal includes transferring assets, including a 150,000-square-foot factory <a href="https://www.benzinga.com/24/12/42323263/wegovy-maker-novo-nordisk-to-buy-novavaxs-czech-republic-manufacturing-facility-for-200-million">and the existing workforce</a>.
Schneider National, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNDR#NYSE">SNDR</a>) disclosed that it has agreed to acquire Cowan Systems, LLC and its affiliates for approximately $390 <a href="https://www.benzinga.com/pressreleases/24/11/b42167845/schneiders-dedicated-momentum-continues-to-build-with-latest-acquisition-of-cowan-systems-llc" target="_blank" rel="noreferrer noopener">million in cash, subject to adjustments</a>. The deal also includes a separate purchase of related real estate <a href="https://www.benzinga.com/news/mid-cap/24/11/42170700/schneider-expands-its-fleet-390-million-cowan-systems-deal-supercharges-dedicated-services">assets for $31 million</a>.
Renewi, a London-listed waste management company, <a href="https://www.macquarie.com/assets/macq/about/company/macquarie-asset-management/project-earth/joint-statement-regarding-a-final-possible-cash-offer-for-renewi-by-macquarie.pdf">agreed</a> to a preliminary takeover offer from Macquarie Asset Management that values it at 700.9 million pounds ($888.8 million). Renewi had been exploring the sale of certain assets (i.e. its <a href="https://www.globenewswire.com/news-release/2024/10/10/2961009/0/en/Completion-of-divestment-of-UK-Municipal-operations.html">UK Municipal division</a>) in order to reduce debt and focus on its core recycling business in the Netherlands, Belgium, France and Portugal.
<h2 class="wp-block-heading">Bankruptcy Block</h2>
Eegee's, a beloved drive-through restaurant chain founded in Tucson in 1971, has filed for Chapter 11 bankruptcy and closed five locations—four in Tucson and one in Phoenix. Despite challenges, Eegee's continues to operate over 20 locations in Tucson and Phoenix. Local media <a href="https://www.kold.com/2024/12/06/eegees-closes-five-restaurants-files-bankruptcy/">reported</a> that the company owes significant debts, including over $1.2 million to Sysco and hundreds of thousands more to other vendors, with total liabilities ranging between $10 million and $50 million. CEO Chris Westcott cited various pressures as reasons for the restructuring, but local residents blamed 39 North Capital, Eegee's owner since 2018.
Trucking company Kal Freight filed for bankruptcy protection, saying its financial condition has been hurt by unprofitable efforts to become a vertically integrated business and a now-questionable investment in additional vehicles during the height of the Covid-19 pandemic. The closely held company also faces litigation, including foreclosure actions, according to the <a href="https://www.wsj.com/articles/trucker-kal-freight-files-for-bankruptcy-protection-06194094">Wall Street Journal</a> citing a filing Thursday in the U.S. Bankruptcy Court in Houston.
Proma Group has <a href="https://www.promagroup.com/archive/news/68">acquired</a> Germany&#8217;s Recaro Automotive GmbH, enabling the company to exit bankruptcy and resume operations across Europe starting January 2025. Recaro's aftermarket seats will return to the market in January, with OEM production shifting to Italy where Proma is based. Several employees from Recaro&#8217;s Sales and Technology departments will remain in the Stuttgart area to ensure a smooth transition and customer support. Recaro&#8217;s operations in North America and Japan remain unaffected. Proma Group CEO Luca Pino praised the partnership as a blend of German industrial and Italian manufacturing excellence.
<h2 class="wp-block-heading">Notes From The Block</h2>
Bain &amp; Company did a swell job putting M&amp;A telecom trends into perspective this week. Here&#8217;s what we learned: 
<ul>
<li>Global deal value &#8220;surged&#8221; from about $24 billion in the first three quarters of 2023 to $90 billion in the same period in 2024, the firm noted. The Americas accounted for 63% of the global total.</li>
<li>Financial investors are acquiring tower and fixed assets. This trend underscores confidence in digital infrastructure's business fundamentals despite headwinds.</li>
<li><a href="https://www.benzinga.com/markets/equities/24/09/40727235/verizon-to-acquire-frontier-in-20b-deal-reaffirms-fy24-outlook">The $20.3 billion deal between</a> Frontier Communications Parent, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FYBR#NASDAQ">FYBR</a>) and Verizon Communications Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VZ#NYSE">VZ</a>) is the year's largest transaction so far.</li>
<li>Scale deals accounted for nearly half of global deal value year to date; infrastructure divestments accounted for 22% of deal value through the first nine months of 2024 (36% of all deal value over the past five years); mobile and fixed divestments made up about 20% during that period. For the full report, <a href="https://www.bain.com/insights/telecom-m-and-a-here-are-the-latest-deal-trends-worldwide-interactive/">click here</a>.</li>
</ul>
For last week&#8217;s <a href="https://www.benzinga.com/news/asset-sales/24/11/42254293/deal-dispatch-stoli-bankrupt-ally-financial-to-sell-credit-card-unit">Deal Dispatch, click here</a>.
Now Read:
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42370712/bitcoins-flash-crash-is-a-classic-bull-market-shakeout-says-trader-watch-these-3-scenarios">Bitcoin Flash Crash: Classic Bull Market Shakeout?</a></li>
</ul>

AMPS

BLCO

BTBT

FYBR

LBPH

LSPD

MSGM

PDCO

SNDR

TCEHY

UBSFF

USAP

Deal Dispatch: Ubisoft In Buyout Talks, Dental Supplier Explores Sale, Beloved Drive-Through Goes Bankrupt

Novavax (NVAX) announced progress in Q4 advancing its corporate growth strategy through its partnership with Sanofi (SNY). The company has achieved...

Novavax advances growth strategy through partnership with Sanofi

Unusual total active option classes on open include: Checkpoint Therapeutics (CKPT), Red Cat Holdings (RCAT), Novavax (NVAX), BlackBerry (BB), Micr...

Unusually active option classes on open December 16th

In a regulatory filing, Novavax (NVAX) disclosed that, on December 12, the company entered into Amendment #5 to the Advanced Purchase Agreement, da...

Novavax says Australia cancels delivery of some Covid-19 doses

It's not a bear market for biotech yet it just feels that way because recent trends are down and healthcare stocks are not a stabilizing force.

Are You Ready To Trade Biotech Stocks At The Cusp Of A Bear Market?

Vaccine stocks gain amid uptick in flu, COVID-19, RSV

Unusual total active option classes on open include: Getty Images (GETY), Nkarta (NKTX), Truist Financial (TFC), Pac Bio (PACB), Enovix (ENVX), Nov...

Unusually active option classes on open January 7th

Moderna, Novavax and other vaccine names extend gains amid COVID/flu concerns

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: Puma...

Biotech Alert: Searches spiking for these stocks today

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include:&nbsp...

Novavax Cashes In On Its COVID Albatross -- Challenges Remain (Rating Upgrade)

ARCT

ARKG

BPAQF

CKPT

CNSP

CRMD

CRNC

ENVX

GETY

HOOD

HOTH

KMDA

MTNB

NKTX

PACB

PBYI

PLUG

RCAT

REGN

RIVN

SLGL

SNYNF

SWTX

TDOC

Press Releases

Novavax to Host Conference Call to Discuss Third Quarter 2024 Financial Results and Operational Highlights on November 12, 2024

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novavax, Inc. - NVAX

U.S. FDA Removes Clinical Hold on Novavax's COVID-19-Influenza Combination and Stand-alone Influenza Phase 3 Trial

Earnings

Novavax Reports Third Quarter 2024 Financial Results and Operational Highlights

Novavax to Participate in Jefferies London Healthcare Conference

Novavax Announces Grant of Inducement Awards Pursuant to Nasdaq Listing Rule 5635(c)(4)

Novavax Announces Sale of Czech Republic Manufacturing Site to Novo Nordisk for $200 Million

Novavax Initiates Phase 3 Trial for COVID-19-Influenza Combination and Stand-Alone Influenza

Contracts

Novavax Advances Corporate Growth Strategy Through Sanofi Partnership, Including Achievement of First $50 Million Milestone

Comments

Novavax

Interés en corto

Novavax (NASDAQ:NVAX) Bolsa, Informe de interés en corto

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL